Physician profile
Tamara Tofte
NPI 1588205934
$3,038.46
in general payments reported to CMS, 2019-2025
27 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,599 · 2022: $829 · 2023: $286 · 2024: $135 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $882.54 | 2021-2025 | |
| Lilly USA, LLC | $469.28 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $268.61 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $168.71 | 2021-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.11 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $152.22 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $145.32 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $119.61 | 2021 | |
| Amarin Pharma, INC. | $82.52 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.71 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $61.07 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $55.57 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $49.42 | 2021-2022 | |
| Amgen INC. | $45.88 | 2021-2024 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company Ltd. | $43.15 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.02 | 2022-2023 | |
| Pfizer INC. | $30.55 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $27.56 | 2021 | |
| Glaxosmithkline, LLC. | $25.68 | 2021-2025 | Trelegy Ellipta |
| Corcept Therapeutics | $22.31 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $19.99 | 2023 | Auvelity |
| Phathom Pharmaceuticals, INC. | $17.92 | 2024 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $17.67 | 2022 | |
| Lundbeck LLC | $17.11 | 2025 | Rexulti |
| Dexcom, INC. | $15.49 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $14.65 | 2022 | |
| Clarus Therapeutics INC. | $5.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Tofte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.